Trials / Unknown
UnknownNCT03882060
Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of recombinant human erythropoietin (rHuEPO) on the neovascularization of pediatric moyamoya disease patients. rHuEPO will be administrated during perioperative period of the first revascularization surgery. Primary outcome (Incidence of Good postoperative MCA territory revascularization by cerebral angiography) will be evaluated after 3-6 month of revascularization surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erythropoietin | Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery. |
| DRUG | Normal saline | Control group, no intervention. |
Timeline
- Start date
- 2019-04-08
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2019-03-20
- Last updated
- 2023-11-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03882060. Inclusion in this directory is not an endorsement.